SecA Inhibitors Block Growth of Methicillin-Resistant Staphylococcus aureus
|
By LabMedica International staff writers Posted on 15 Dec 2015 |

Image: Colorized scanning electron micrograph (SEM) shows a grouping of methicillin resistant Staphylococcus aureus (MRSA) bacteria magnified 20,000 times (Photo courtesy of the CDC – US Centers for Disease Control and Prevention).
A novel class of low molecular weight compounds has been shown to effectively inhibit the growth of methicillin-resistant Staphylococcus aureus (MRSA), one of the most serious drug-resistant bacterial pathogens.
Investigators at Georgia State University (Atlanta, USA) had shown previously that small molecular components of the dye Rose Bengal (RB) were active against the bacteria Escherichia coli and Bacillus subtilis. This activity was found to be due to inhibition of SecA, a cell membrane-associated subunit of the eubacterial Sec or Type II secretory pathway, a system which is responsible for the secretion of proteins through the cell membrane. Within this system SecA has the functional properties of an ATPase and is required to empower the movement of the protein substrate across the translocation channel. Thus, SecA is a key component of the general bacterial secretion system required for viability and virulence.
In the current study, which was published in the November 1, 2015, issue of the journal Bioorganic & Medicinal Chemistry, the investigators evaluated two potent RB analogs for activities against MRSA strains and for their mechanism of actions.
These analogs inhibited the ATPase activities of S. aureus SecA1 (SaSecA1) and SecA2 (SaSecA2), and inhibited the SaSecA1-dependent protein-conducting channel. Moreover, these inhibitors reduced the secretion of three toxins from S. aureus and exerted potent bacteriostatic effects against three MRSA strains.
The best inhibitor, SCA-50, showed potent concentration-dependent bactericidal activity against MRSA Mu50 strain and very importantly, two to 60-fold more potent inhibitory effect on MRSA Mu50 than all the commonly used antibiotics including vancomycin, which is considered the last resort option in treating MRSA-related infections.
Deletion or overexpression of bacterial efflux pumps had minimal effect on the antimicrobial activities against S. aureus, indicating that the effects of SecA inhibitors were not affected by the presence of these efflux pumps. This study showed that these small molecule analogs of Rose Bengal targeted SecA functions, had potent antimicrobial activities, reduced the secretion of toxins, and had the ability to overcome the effect efflux pumps, which are responsible for multi-drug resistance.
"We have found that SecA inhibitors are broad-spectrum antimicrobials and are very effective against strains of bacteria that are resistant to existing antibiotics," said contributing author Dr. Binghe Wang, professor of chemistry at Georgia State University.
Related Links:
Georgia State University
Investigators at Georgia State University (Atlanta, USA) had shown previously that small molecular components of the dye Rose Bengal (RB) were active against the bacteria Escherichia coli and Bacillus subtilis. This activity was found to be due to inhibition of SecA, a cell membrane-associated subunit of the eubacterial Sec or Type II secretory pathway, a system which is responsible for the secretion of proteins through the cell membrane. Within this system SecA has the functional properties of an ATPase and is required to empower the movement of the protein substrate across the translocation channel. Thus, SecA is a key component of the general bacterial secretion system required for viability and virulence.
In the current study, which was published in the November 1, 2015, issue of the journal Bioorganic & Medicinal Chemistry, the investigators evaluated two potent RB analogs for activities against MRSA strains and for their mechanism of actions.
These analogs inhibited the ATPase activities of S. aureus SecA1 (SaSecA1) and SecA2 (SaSecA2), and inhibited the SaSecA1-dependent protein-conducting channel. Moreover, these inhibitors reduced the secretion of three toxins from S. aureus and exerted potent bacteriostatic effects against three MRSA strains.
The best inhibitor, SCA-50, showed potent concentration-dependent bactericidal activity against MRSA Mu50 strain and very importantly, two to 60-fold more potent inhibitory effect on MRSA Mu50 than all the commonly used antibiotics including vancomycin, which is considered the last resort option in treating MRSA-related infections.
Deletion or overexpression of bacterial efflux pumps had minimal effect on the antimicrobial activities against S. aureus, indicating that the effects of SecA inhibitors were not affected by the presence of these efflux pumps. This study showed that these small molecule analogs of Rose Bengal targeted SecA functions, had potent antimicrobial activities, reduced the secretion of toxins, and had the ability to overcome the effect efflux pumps, which are responsible for multi-drug resistance.
"We have found that SecA inhibitors are broad-spectrum antimicrobials and are very effective against strains of bacteria that are resistant to existing antibiotics," said contributing author Dr. Binghe Wang, professor of chemistry at Georgia State University.
Related Links:
Georgia State University
Latest BioResearch News
- Lung Tumor RNA Variants Offer Clues to Immunotherapy Benefit
- Population-Scale Genome Survey Supports Interpretation of Genetic Testing
- Single-Cell Profiling Reveals Chemotherapy Resistance Signals in Ovarian Cancer
- Genomic Tool Supports Analysis of Repeat Expansions Linked to Inherited Disorders
- CSF Biomarker Meprin-Beta Increases in Alzheimer’s Disease
- Cancer DNA Trapping Mechanism Reveals Potential Target for Future Therapies
- Blood Antibody Signals May Offer Clues to the Origins of Childhood Cancer
- Genetic Study Links Inherited Blindness to Gene Tied to Rare Metabolic Disorder
- Population-Scale Proteomics Study Identifies New Genetic-Protein Links
- Circulating Tumor DNA Helps Identify Targets for Personalized Immunotherapy
- Researchers Classify 108 Lysosomal Disorders in Updated Diagnostic Framework
- New Autoantibody Target Identified in Neuromyelitis Optica Spectrum Disorder
- New Immune Target Could Support More Precise High Blood Pressure Treatment
- New Gene-Disease Link May Help Diagnose Rare Neurodevelopmental Disorders
- Researchers Identify Shared Molecular Networks Behind Fatigue-Related Illnesses
- Blood Metabolite Signature Predicts ALS Progression and Points to Treatment Strategy
Channels
Clinical Chemistry
view channel
Blood Proteins Linked to Mortality Risk and Biological Aging Across Organ Systems
Older adults of the same chronological age can differ markedly in health, chronic disease burden, and resilience. Biological age aims to capture these differences by reflecting how rapidly the body and... Read more
Two-Step Blood Test Improves Specificity for Alzheimer’s Diagnosis
Early Alzheimer’s disease can be difficult to identify before more severe cognitive symptoms emerge. Blood tests measuring phosphorylated tau protein p-tau217 may help detect disease-related changes, but... Read moreMolecular Diagnostics
view channel
Spinal Fluid Liquid Biopsy May Help Clarify Uncertain Brain Tumor Findings
Brain and spinal cord tumors can be difficult to diagnose when imaging is inconclusive or tissue biopsy cannot be performed safely. MRI changes may reflect cancer, inflammation, or treatment-related effects,... Read more
New NGS Panel Detects AML Fusions at MRD-Level Sensitivity
Genomic testing for acute myeloid leukemia (AML) can be limited by incomplete coverage of disease-associated alterations. Fusion events may remain undetected when workflows rely on multiple assays or lack... Read more
Updated Framework Guides Assessment of Actionable Cancer Biomarkers
Cancer care increasingly relies on molecular testing to guide targeted treatment selection. Broader use of tumor sequencing has expanded the volume and diversity of biomarker data available to oncologists,... Read more
Genomic Tissue Test Predicts Metastasis and Abiraterone Benefit in High-Risk Prostate Cancer
Prostate cancer is the most common cancer in men, affecting more than 1 million men worldwide in 2013. Its clinical course varies substantially between patients, complicating efforts to identify those... Read moreHematology
view channel
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read more
New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially... Read moreImmunology
view channel
Immune and Inflammatory Markers May Help Assess CAR T-Cell Complication Risk
Cytokine release syndrome (CRS) can occur after chimeric antigen receptor (CAR) T-cell therapy in patients with autoimmune disease. Identifying which patients are more likely to develop this complication... Read more
COVID-19 and Flu Combo Test Launches With FDA Clearance
Overlapping symptoms of COVID-19 and influenza can create diagnostic uncertainty, particularly in urgent and point-of-care settings. Rapid differentiation from a single specimen can streamline triage and... Read moreMicrobiology
view channel
Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea
Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read more
Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
The ongoing Ebola Bundibugyo outbreak in the Democratic Republic of the Congo and neighboring countries has become one of the largest outbreaks of this Ebola virus species recorded to date.... Read morePathology
view channel
Roche Launches Automated Test to Support Mesothelioma Differential Diagnosis
Mesothelioma is a rare, deadly cancer that forms in the tissue lining many internal organs. Most patients are diagnosed late, with median overall survival reported at 12 to 18 months. Differential diagnosis... Read more
Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. However, individual risks... Read more
AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
High-grade serous tubo-ovarian carcinoma is an aggressive cancer arising in the ovaries or fallopian tubes. Some tumors exhibit homologous recombination deficiency (HRD), a feature reflecting impaired DNA repair.... Read moreTechnology
view channel
Compact PCR Thermal Cycler Launches for Routine Molecular Laboratory Workflows
Molecular laboratories rely on nucleic acid analysis to detect molecular information accurately and reproducibly across a wide range of applications. Supporting these routine workflows, a newly launched... Read more
New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows
Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read moreIndustry
view channel
Collaboration Brings Tumor-Informed MRD Monitoring to Breast Cancer Care in Abu Dhabi
For many patients, cancer treatment does not eliminate the risk of recurrence, which may occur months or years later and become harder to treat after spreading. Recurrence is often detected only after... Read more







